Fear of clofazimine-induced skin discoloration as a barrier to leprosy treatment: urgent need for alternative therapeutic options
Clicks: 4
ID: 323626
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
4 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #48 of 169 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 169 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Since 1982, the WHO recommends multi-drug therapy (MDT) fconsisting of three antibiotic drugs, namely rifampicin, dapsone and clofazimine. While MDT is effective, its adverse effects are underrecognized. Clofazimine causes near-universal skin discoloration, and is a key barrier to treatment acceptance and adherence because it visibly discloses leprosy. Using two compelling case studies in which MDT was declined or discontinued due to fears that clofazimine-induced dyspigmentation would reveal leprosy status and harm family reputation, we highlight the challenges posed by clofazimine and the limited availability of alternative treatment options in resource-constrained settings.
| Reference Key |
openalex_W7172451063
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nindya N Utami, Sri Vitayani Muchtar, Hana Krismawati, Anita L Patinggi, Mutia Rahardjani, Aliza N Mulyadi, Dian E Hasvitasari, Jennifer I. Van Nuil, Stephen L. Walker, Hardyanto Soebono, Marlous L. Grijsen |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag349
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.